|
|
SLA-SE |
|
Vaxjo ID |
195 |
|
Vaccine Adjuvant Name |
SLA-SE |
|
Adjuvant VO ID |
VO_0005423
|
|
Description |
stable squalene-based oil-in-water emulsion of a chemically synthesized toll-like receptor 4 (TLR4) agonist, second-generation lipid adjuvant (SLA) that induces Th1 response |
|
Stage of Development |
Clinical Trial |
|
Location Licensed |
US (AAHI) |
|
Host Species for Testing |
2 |
|
Second Host Species for Testing |
3 |
|
Components |
SLA and squalene |
|
Storage |
2-8C |
|
Preparation |
stable oil in water emulsion of SLA |
|
Function |
innate immune activation |
| References |
(Soza, 2024): Vaccine Adjuvant Compendium - VAC [https://vac.niaid.nih.gov/view?id=65]
Cookenham et al., 2020: Cookenham T, Lanzer KG, Gage E, Lorenzo EC, Carter D, Coler RN, Baldwin SL, Haynes L, Reiley WW, Blackman MA. Vaccination of aged mice with adjuvanted recombinant influenza nucleoprotein enhances protective immunity. Vaccine. 2020; 38(33); 5256-5267. [PubMed: 32540272].
Nam et al., 2022: Nam HJ, Hong SJ, Lee A, Kim J, Lee S, Casper C, Carter D, Reed SG, Simeon G, Shin EC. An adjuvanted zoster vaccine elicits potent cellular immune responses in mice without QS21. NPJ vaccines. 2022; 7(1); 45. [PubMed: 35459225].
|
|
